Drug pricing is emerging as a key challenge for Novo Nordisk, the world’s biggest insulin producer, whose previously unstoppable growth has started to flag, according to the Danish firm’s chief executive. Lars Sorensen is certain of one thing: the number of potential customers for his products is going to keep on rising as a global obesity epidemic tips more people into type 2 diabetes in the West and many developing nations.
Help employers find you! Check out all the jobs and post your resume.
